Eton Pharmaceuticals, Inc. 8-K

What Happened

• Eton Pharmaceuticals (ETON) filed an 8-K on April 16, 2026 announcing the appointment of Judith Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer, Corporate Secretary and Treasurer effective June 1, 2026, succeeding James Gruber. Mr. Gruber will remain in his role through May 31, 2026 and then enter a six-month consulting agreement with the company.

Key Details

• Effective date: June 1, 2026 (transition through May 31, 2026 for current CFO).
• Compensation: $440,000 annual base salary and an annual discretionary incentive bonus with a target of 45% of base salary.
• Equity: one-time option to purchase 37,000 shares, vesting in equal annual installments over four years (inducement grant).
• Corporate governance: appointment not pursuant to any third‑party arrangement; no family relationships or reportable related‑party transactions disclosed.

Why It Matters

• This is a material executive leadership change in Eton’s finance team that could affect how investors view the company’s financial stewardship and reporting going forward. The planned overlap and six‑month consulting arrangement with the outgoing CFO provide continuity during the transition. Compensation and equity grant tie the new CFO’s incentives to company performance and long‑term alignment with shareholders. Investors should monitor future filings and company updates for any commentary on financial strategy, guidance, or impacts tied to the leadership change.